Track topics on Twitter Track topics that are important to you
Today's Daily Dose brings you news about expanded FDA approval for Allergan's schizophrenia drug; post-hoc analysis of Lilly's EMPA-REG OUTCOME trial; Court ruling against MediWound; extension of FDA's decision deadline by 3 months on Theratechnologies' biologics license application, TRACON's phase I data and Zymeworks' deal with Janssen Biotech.
Original Article: FDA Nod For AGN, ZYME Strikes A Deal With Janssen Biotech, TCON AbuzzNEXT ARTICLE
Schizophrenia is a common serious long-term mental health condition that affects 5 in 1000 in the UK. It causes a range of different psychological symptoms; hallucinations, delusions, muddled thoughts based on the hallucinations or delusions and ch...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...